Start with the actual preparation
A provider page may show a vial, a testing badge and a general description of its pharmacy partners. Before interpreting those claims, identify what would actually be prescribed and dispensed: the ingredient, route, concentration, container and pharmacy. A statement about one formulation should not automatically be carried over to another product on the same website.
Ask who can answer product-quality questions after dispensing. The platform handling appointments may not be the pharmacy that prepared the medication. Keeping the prescriber, service company and dispensing pharmacy distinct makes it easier to direct questions about storage, labeling, a damaged shipment or the documentation associated with a particular order.
Understand what each test addresses
Potency testing concerns the amount of a substance measured against a specification. Sterility and endotoxin testing address different quality concerns. A page displaying all three does not establish that the same report covers the reader's actual preparation, nor does it show that every relevant manufacturing control has been independently evaluated by this publication.
IVY RX, for example, advertises several quality tests on its NAD+ pages. A useful follow-up is whether documentation exists for the product being dispensed, how the lot is identified and which laboratory performed the work. A broad badge, a facility registration and a batch-specific record answer different questions and should not be treated as interchangeable evidence.
Why FDA's NAD+ notice matters
FDA has warned about food-grade NAD+ being used to prepare sterile intravenous products without appropriate processing. The agency identifies contamination with microbes and endotoxins as concerns and describes reported reactions following injectable NAD+ use. This is a specific quality issue, distinct from whether a provider's proposed wellness benefit is supported by clinical research.
The notice does not establish that every NAD+ product is contaminated or that a named provider in this guide has caused those events. It does justify asking how ingredients are sourced and whether they are suitable for the preparation. Keep the scope accurate: a warning about sterile products should not be converted into a claim about an untested nasal bottle.
Registration is not product approval
FDA explains that compounded drugs do not undergo its premarket approval process for safety, effectiveness and quality. A facility's registration or a reference to pharmacy licensure does not change the approval status of the finished compounded drug. Likewise, a clinician's prescription does not provide missing evidence of benefit for a particular use.
Ask the prescriber why the preparation is being considered and what evidence supports the proposed purpose and route. Quality documentation and clinical justification are both relevant, but neither substitutes for the other. A well-documented manufacturing test cannot demonstrate that a product improves energy, cognition or longevity in the person considering it.
Turn documentation into usable questions
Before accepting a shipment, know where the pharmacy's storage instructions and beyond-use date will appear and whom to contact if the package is delayed or damaged. Follow the actual label and clinical advice rather than estimating stability from a review or a different provider's shipping policy. Request clarification when the instructions and package do not agree.
Keep the pharmacy contact and relevant order details available for follow-up. If a reaction or urgent health concern occurs, seek appropriate medical assessment rather than trying to solve it with a certificate or online comparison. This checklist helps readers examine claims and communicate clearly; it does not certify a product or teach sterile preparation.
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.